Citations

Clear

9383 citation(s) found for "Thomas, PS".

1035 Automated Analysis of REM Sleep Without Atonia in the Lewy Body Disease Spectrum
Jagielski, Jack, Kelleher, M., Finstuen, Thomas, Kejal, Kantarci, Michael, Silber, Dredla, Brynn K., Kelleher, Makayla, Leclair‐Visonneau, Laurène , McCarter, Stuart J. , Boeve, Bradley F. , Michael, Silber, Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A445-A445

10.1093/sleep/zsae067.01035 Get It

Abstract Introduction Quantitative rapid eye movement (REM) sleep without atonia (RSWA) recorded during polysomnography (PSG) represents loss of normal REM sleep atonia. RSWA is the neurophysiologic signature of REM sleep behavior disorder (RBD). Visually scored RSWA is a candidate biomarker for synucleinopathies. However, visual RSWA scoring requires expert scoring, limiting widespread application. We comparatively analyzed RSWA in DLB and iRBD using the automated Ferri REM Atonia Index (RAI). Methods We quantitatively analyzed the RAI in 17 DLB and 20 iRBD patients, compared to 20 controls using Hypnolab Software for Sleep Analysis (SWS Soft, Colognola ai Colli, Italy). PSG data were converted to European Data Format (.EDF), and the submentalis surface electromyogram (EMG) signal was notch-filtered at 60 Hertz and rectified. Automatically calculated RAI scores were comparatively analyzed across groups (DLB, iRBD, controls) using Kruskal Wallis H tests for group comparisons, and regression analyses determined relationships between diagnosis, age, and sex. Logistic regression ROC determined optimal RAI for distinguishing iRBD from DLB. When interpreting RAI, lower values represent greater amounts of RSWA, and higher values represent more normal REM atonia. Results Median age was no different between DLB (72.6 years), iRBD (69.4 years), and controls (68.0 years). The DLB group consisted of 16 men and one woman, the iRBD group had 18 men and 2 women, and controls were comprised of 16 men and 4 women. Median RAI was lowest in DLB (0.32), intermediate in iRBD (0.84) and highest in controls (0.96), indicating a gradient in RSWA amounts from DLB patients (highest) to controls (lowest). Regression demonstrated diagnosis independently predicted RAI, controlling for age and sex (adjusted R2=0.64, p=0.0001). The RAI that optimally distinguished iRBD from DLB was 0.48 (specificity 85%, sensitivity 76%, AUC=0.88). Conclusion The RAI demonstrated a clear gradient throughout the Lewy body spectrum; highest (indicating lowest RSWA amounts) in controls, intermediate in iRBD, and lowest (indicating greatest RSWA) in DLB. The RAI is a promising, time efficient and broadly applicable candidate biomarker for DLB and iRBD. Automated quantitative RSWA could be a valuable tool for deep phenotyping throughout the Lewy body disease spectrum. Support (if any) This study was supported by: U01NS100620, R34AG056639, U19AG071754, and P30AG62677.
1013 Cross Validation of Sleep Biomarker Based Phenotyping of Neurodegenerative Disorders
Levendowski, Daniel J. , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazeika, Gandis, Neylan, Thomas C. , Yack, Leslie M. , Tsuang, Debby W. , Berka, Chris , Mazeika, Gandis, Boeve, Bradley F. , Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A435-A436

10.1093/sleep/zsae067.01013 Get It

Abstract Introduction n this cross-validation study, the distributions of sleep biomarker-based neurodegenerative disorder (NDD) risk were evaluated across a spectrum of NDD patients and presumed controls which were independent of the model development dataset. Methods Variables that included age, time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha obtained with Sleep Profiler were used to train a 4-class machine learning algorithm that generated probabilities of NDD risk for the groups: Alzheimer’s dementia (AD), Lewy body disorder (LBD), prodromal synucleinopathy (pSYN based on REM sleep behavior disorder patients), and controls (CG). Records with CG output probabilities >70% were labeled Probably-normal, and from 45-70% Likely-normal with indications of a NDD added when the LBD, AD or pSYN risks exceeded approximately 25%. Similar thresholds were used to assign Likely- or Probable- LBD, AD, pSYN or Mixed based on the group probabilities. This cross-validation study was designed to use datasets that were independent of those used to train the classification algorithm. Thus, NDD risk distributions were evaluated in patients with mild cognitive impairment (MCI=71), Parkinson’s disease (PD=16), progressive supranuclear palsy (PSP=21) and control subjects (NC=41) with Mini-Mental State Exam scores>28 and/or normal for MCI by Petersen criteria. Results In the MCI group, NDD risk assignments were Probable-AD=26%, -Mixed=10%, -LBD=1%, Likely-AD= 7%, -Mixed=6%, -LBD=3%, -pSYN=1%, Likely-Normal indications-AD=9%, -pSYN=7%, -Mixed=4%, and Probably-Normal=26% In the PSP group, Probable-LBD=43%, -Mixed=29% and -pSYN=4%, Likely-Mixed=10%, Likely-Normal indications AD=10%, and Probably-Normal=4%. In the PD group, Probable-LBD=13%, -pSYN=13%, -AD=6%, Likely-Mixed=19%, -pSYN=6%, Likely-Normal Indications-pSYN=19%, -AD=12%, Likely-Normal=6% and Probably-Normal=6% In the NC group, 83% were assigned minimal NDD risk with Probably-Normal=70%, Likely-Normal plus indications=13%, but with Likely NDD=13% and Probable NDD=4%. Conclusion NDD risks were disbursed in a manner consistent with the range of severities expected In MCI and PD groups, with 25% exhibiting relatively normal sleep patterns. Over 70% of the PSP patients exhibited probable NDD risk, with patterns similar to those with LBD. The NC NDD risk distributions were consistent with those assigned to the CG used for model development. Support (if any) NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, R34AG056639.
1012 Concordance and Test-Retest Consistency of Sleep Biomarker Based Phenotyping of Neurodegenerative Disorders
Levendowski, Daniel J. , Walsh, Christine M. , Cho, Yeilim, Lee‐Iannotti, Joyce , Mazeika, Gandis, Yack, Leslie M. , Tsuang, Debby W. , Berka, Chris , Mazeika, Gandis, Boeve, Bradley F. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A435-A435

10.1093/sleep/zsae067.01012 Get It

Abstract Introduction In this pilot study, the diagnostic agreement for sleep biomarker-based neurodegenerative disorder (NDD) risk probabilities was evaluated in patients with Alzheimer’s disease dementia (AD), Lewy Body disease (LBD), and isolated REM sleep behavior disorder (iRBD) and controls with a Mini-Mental State Exam scores>28. Methods Sleep biomarkers recorded with the Sleep Profiler (Advanced Brain Monitoring, Inc) were used as inputs to a 4-class machine learning algorithm trained to assign NDD risk probabilities to AD=27, LBD=19, iRBD=15 and controls (CG=58). Input variables included age, time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Records with CG output probabilities >70% were labeled Probably-normal, and from 45-70% Likely-normal with indications of a NDD added when the LBD, AD or prodromal synucleinopathy (pSYN) risks exceeded approximately 25%. Similar thresholds were used to assign Likely- or Probable- LBD, AD, or pSYN based each of the group probabilities. Classification accuracies were evaluated in AD=37, LBD=19, iRBD=19 and CG=61 records. Longitudinal test-retest reliabilities were assessed for CG (n=45, range 8-56 months), and after six-months for LBD (n=10) and AD (n=9). Results In the AD group, NDD risk assignments were consistent with diagnoses=85%, with Probable-NDD=59%, Likely-NDD=11%, Normal plus AD/Mixed indications=15%, but with 5%=Probably-normal. In the LBD group, assigned risks were consistent with the diagnosis=79%, with Probable-NDD=74%, Normal with pSYN indications=5%, but with 11%=Probably-normal. In the iRBD group, Probable-NDD=42%, Normal plus pSYN indications=26% and Probably-normal=32%. In the CG group, 89% were assigned minimal NDD risks with Probably-normal=67%, Normal plus indications=22%, but with Likely NDD=8% and Probable NDD=3%. The AD test-retest reliability showed the same NDD classifications=78%, with slightly increasing=11% and decreased=11%. In the LBD group, the same NDD classifications were achieved=80%, with trending equivalence=10%, and decreasing severity=20%. The CG test-retest reliability showed the same NDD classifications=76%, with trending equivalence=22%, and increased severity=2%. Conclusion Consistencies between the diagnoses and assigned NDD risks and test-retest classification agreements were approximately 80% in the AD, LBD, and CG groups. In the iRBD group, the NDD risks were disbursed consistent with the range of expected severities. These results needed to be cross-validated in independent NDD datasets. Support (if any) NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, R34AG056639.
0753 Relationship Between OSA and Sleep Biomarker Based Neurodegenerative Disorder Risk in a Clinical Cohort
Mazeika, Gandis, Cho, Yeilim, Anderson, Jack , Levendowski, Daniel J. , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazeika, Gandis, Tsuang, Debby W. , Neylan, Thomas C. , Lewis, Simon J.G. , Louis, Erik K. St.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A322-A323

10.1093/sleep/zsae067.0753 Get It

Abstract Introduction In this pilot study, sleep biomarker-based neurodegenerative disorder (NDD) risk was assessed in a clinical cohort of patients diagnosed with varying severity of obstructive sleep apnea (OSA). Methods Consecutive in-home multi-night Sleep Profiler records from a community sleep clinic were screened for age >54 years old. Cases with comorbid restless leg syndrome, hypersomnia, missing apnea-hypopnea indexes (AHI), AHI< 5 or single-night recordings were excluded. The 67 remaining records were 40% female, ages 63 + 7.4 years and up to 84 years old. NDD risk was assigned using a machine-learning algorithm combining age and nine sleep biomarkers to assign group probabilities: for Alzheimer’s disease, Lewy Body disease, prodromal synucleinopathy and controls (CG). Sleep biomarkers included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Those with CG probability score >70% were classified as “Probably-normal”. Those with CG probability between 45 - 70% were classified as “Likely-normal”. Insomnia severity >14 and a PHQ 9 > 5 were used as cutoffs for clinical insomnia and depression. Mann-Whitney U-tests were used to evaluate group differences. Results This cohort had 37% mild, 34% moderate, and 29% severe OSA. Self-reported comorbid insomnia and depression were present in 43%. Seventy-three percent of patients were classified as “Probably-normal”, 16% “Likely-normal”, 11% “Likely-NDD” or “Probable-NDD”. The “Probably-normal” group was younger than the rest of the cohort (62 + 6.2 years vs. 68 + 8.6 years, p< 0.01). Of those classified as “Probably-normal” (n=49), OSA was mild in 16, moderate in 17 and severe in 16. Mean AHI trended higher in the “Probably-normal” group than in those with elevated NDD risk (29 + 23.9 vs. 19 + 13.6 events/h, p=0.085). Conclusion Approximately 89% of the clinical cohort was classified as “Probably-normal” or “Likely-normal”. NDD risk was age-dependent. Interactions between OSA severity and NDD risk were not apparent in these findings, possibly related to group-wide effects. NDD risk, as measured by this model, did not appear to be adversely biased by untreated OSA. These results suggest a need for longitudinal studies to compare NDD risk in untreated OSA versus controls without sleep disordered breathing. Support (if any) NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, and R34AG056639.
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Stearns, Vered , Jegede, Opeyemi A. , Chang, Victor T. , Skaar, Todd C. , Berenberg, Jeffrey L. , Nand, Ranveer , Shafqat, Atif , Jacobs, Nisha L. , Luginbuhl, William , Gilman, Paul , Benson, Al B. , Goodman, Judie R. , Buchschacher, Gary L. , Henry, N. Lynn , Loprinzi, Charles L. , Flynn, Patrick J. , Mitchell, Edith P. , Chang, Victor T-S , Fisch, Michael J , Sparano, Joseph A , Wagner, Lynne , Jagede, Opeyemi A. , Henry, N Lynn , Stearns, Vered , Fisch, Michael , Sparano, Joseph A. , Wagner, Lynne I.

Mayo Clinic

Clinical Cancer Research | April 19, 2024 | Volume: 30 | Issue: 13 | Pages: 2709-2718

10.1158/1078-0432.ccr-23-2137 | PMID 38640040 Get It

Abstract Purpose: Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohort study designed to validate the association between 10 SNPs and AI discontinuation due to AIMSS. Patients and Methods: Postmenopausal women with stage I to III hormone receptor–positive breast cancer received anastrozole 1 mg daily and completed patient-reported outcome measures to assess AIMSS (Stanford Health Assessment Questionnaire) at baseline, 3, 6, 9, and 12 months. We estimated that 40% of participants would develop AIMSS and 25% would discontinue AI treatment within 12 months. Enrollment of 1,000 women with a fixed number per racial stratum provided 80% power to detect an effect size of 1.5 to 4. SNPs were found in ESR1 (rs2234693, rs2347868, and rs9340835), CYP19A1 (rs1062033 and rs4646), TCL1A (rs11849538, rs2369049, rs7158782, and rs7159713), and HTR2A (rs2296972). Results: Of the 970 evaluable women, 43% developed AIMSS and 12% discontinued AI therapy within 12 months. Although more Black and Asian women developed AIMSS than White women (49% vs. 39%, P = 0.017; 50% vs. 39%, P = 0.004, respectively), the AI discontinuation rates were similar across groups. None of the SNPs were significantly associated with AIMSS or AI discontinuation in the overall population or in distinct cohorts. The OR for rs2296972 (HTR2A) approached significance for developing AIMSS. Conclusions: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, patient-reported outcome predictors of AIMSS, and differences by race.
A Roadmap for Therapeutic Discovery in Pulmonary Hypertension Associated with Left Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
Pollesello, Piero , Anker, Markus S. , Backs, Johannes , Bayés‐Genís, Antoni , González, Aránzazu , Maack, Cristoph, Madden, Brendan , Redfield, Margaret M. , Rich, Stuart , Schiattarella, Gabriele G. , Skaara, Hall, Stellos, Konstantinos , Vachiéry, Jean Luc, Meer, Peter van der, Linthout, Sophie Van , Pruszczyk, Piotr , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Tocchetti, Carlo G. , Schiattarella, Gabriele G. , Stellos, Konstantinos , Metra, Marco , Tocchetti, Carlo Gabriele , Ameri, Pietro , Mercurio, Valentina , Borlaug, Barry A. , Burkhoff, Daniel , Caravita, Sergio , Chan, Stephen Y. , Man, Frances S. de , Giannakoulas, George , Guazzi, Marco , Hassoun, Paul M. , Hemnes, Anna R. , Melenovský, Vojtěch , Müller, Oliver Josef , Papp, Zoltán , Pullamsetti, Soni Savai , Rainer, Peter P. , Tedford, Ryan J. , Thum, Thomas , Vachiéry, Jean‐Luc , Meer, Peter van der , Coats, Andrew J.S. , Rosenkranz, Stephan

Mayo Clinic

European Journal of Heart Failure | April 19, 2024 | Volume: 26 | Issue: 4 | Pages: 707-729

10.1002/ejhf.3236 | PMID 38639017 Get It

Abstract Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes
Beck, Roy W. , Levy, Carol J. , Kudva, Yogish C. , Pandit, Keta, Blevins, Thomas , Raghinaru, Dan, Pinsker, Jordan E. , Levy, Carol J , Beck, Roy W

Mayo Clinic

Clinical Diabetes | April 17, 2024 | Volume: 42 | Issue: 4 | Pages: 547-549

10.2337/cd23-0107 | PMID 39429449 Get It

Timely Completion of Direct Access Colonoscopy Is Noninferior to Office Scheduled for Screening and Surveillance
White, Mary, Israilevich, Rachel , Lam, Sophia , McCarthy, Michael , Mico, Vasil, Chipkin, Benjamin , Abrams, Eric, Moore, Kelly , McCarthy, Michael, Moore, Kelly, Kastenberg, David

Mayo Clinic

Journal of Clinical Gastroenterology | April 17, 2024 | Volume: 59 | Issue: 3 | Pages: 219-226

10.1097/mcg.0000000000002000 | PMID 38630852 Get It

Goals: We aimed to evaluate whether direct access colonoscopy (DAC) is noninferior to office-scheduled colonoscopy (OSC) for achieving successful colonoscopy. Background: DAC may improve access to colonoscopy. We developed an algorithm assessing eligibility, risk for inadequate preparation, and need for nursing/navigator assistance. Study: This was a retrospective, single-center study of DAC and OSC patients from June 5, 2018, to July 31, 2019. Patients were 45 to 75 years old with an indication of screening or surveillance. A successful colonoscopy met 3 criteria: complete colonoscopy (cecum, anastomosis, or ileum), adequate preparation (Boston Score ≥2/segment), and performed <90 days from initial patient contact. Unsuccessful colonoscopy did not meet ≥1 criteria. Secondary end points included days to successful colonoscopy, preparation quality, polyp detection, and 10-year recall rate. Noninferiority against risk ratio value of 0.85 was tested using 1-sided alpha of 0.05. Results: A total of 1823 DAC and 828 OSC patients were eligible. DAC patients were younger, with a greater proportion of black patients and screening indications. For the outcome of successful colonoscopy, DAC was noninferior to OSC (DAC vs. OSC: 62.7% vs. 57.1%, RR 1.16, 95% LCL 1.09, P=0.001). For DAC, days to colonoscopy were fewer, and likelihood of 10-year recall after negative screening greater. Boston Score and polyp detection were similar for groups. Black patients were less likely to achieve successful colonoscopy; otherwise, groups were similar. For unsuccessful colonoscopies, proportionally more DAC patients canceled or no-showed while more OSC patients scheduled >90 days. DAC remained noninferior to OSC at 180 days. Conclusions: DAC was noninferior to OSC for achieving successful colonoscopy, comparing similarly in quality and efficiency outcomes.
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Roh, Jason D. , Castro, Claire , Yu, Andy, Rana, Sarosh , Shahul, Sajid , Gray, Kathryn J. , Honigberg, Michael C. , Ricke‐Hoch, Melanie , Iwamoto, Yoshiko , Yeri, Ashish, Guerra, Justin Ralph Baldovino , Hobson, Ryan , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Lerchenmüller, Carolin , Sayed, Zeina R. Al , Verdugo, Carmen Diaz , Xia, Peng , Skarbianskis, Niv, Zeisel, Amit , Kirkland, James L. , Gorcsan, John , Damp, Julie B., Hanley‐Yanez, Karen , McNamara, Dennis M. , Investigators, for the IPAC, Rosenzweig, Anthony , Fett, James D., Pisarcik, Jessica, McTiernan, Charles F. , Alharethi, Rami , Rasmusson, Kismet, Brunisholz, Kim , Butler, Amy L., Budge, D., Kfoury, Abdallah G., Horne, Benjamin D. , Tuinei, Joe, Brown, Heather , Naftilan, Allen J., Russell, Jill , Freehardt, Darla, Hsich, Eileen , Oblak, Cynthia, Ewald, Greg, Whitehead, Donna, Flanagan, Jean, Platts, Anne, Mullin, Stephanie, Givertz, Michael M. , Anello, Mary Susan, Booth, David R. , Sandlin, Tiffany, Wijesiri, Wendy, Blauwet, Lori A., Brunner, Joann, Phelps, Mary, Kempf, Ruth, Modi, Kalgi , Norwood, Tracy, Griza, Decebal Sorin, Adams, Patricia L., Thohan, Vinay , Wesley-Farrington, Deborah, Soots, Sandra, Sheppard, Richard , Lapointe, Nathalie, Nathaniel, Heather, Kealey, Angela, Semigran, Marc J., Daher, Maureen, Silber, David, Popjes, Eric , Frey, Patricia, Nicklas, Todd, Alexis, Jeffrey D. , Caufield, Lori, Thornton, John W., Gentry, Mindy, Robinson, V.J. , Sharma, Gyanendra K. , Holloway, Joan, Powell, Maria, Markham, David W. , Fernandez, Lynn, Gimovsky, Martin L., Hochbaum, Natalia, Patel, Bharati Kadamb , Adams, Laura , Ramani, Gautam , Robinson, Shawn , Fisher, Stacy D. , Marshall, Joanne, Haythe, Jennifer , Mancini, Donna , Bijou, Rachel, Marks, Marybeth, Arango, Henry, Bolos, Mariana, Mather, Paul , Rubin, Sharon, Bonita, Raphael , Eberwine, Susan, Skopicki, Hal A. , Stergiopoulos, Kathleen , McCathy-Santoro, Ellen, Intravaia, Jennifer, Maas, Elizabeth W., Safirstein, Jordan, Martinez, Nancy , Corpoin, Christine, Hesari, Donna, Chaparro, Sandra , Hudson, Laura J., Ghali, Jalal K. , Injic, Zora, Wittstein, Ilan S. , Kitchen, Robert , Guerra, Justin Baldovino , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Al Sayed, Zeina R , Diaz Verdugo, Carmen , Xia, Peng , Zeisel, Amit , Bauersachs, Johann , Kirkland, James L , Karumanchi, S Ananth , Gorcsan, John , Sugahara, Masataka , Hanley-Yanez, Karen , Ellinor, Patrick T , Arany, Zoltan Pierre , McNamara, Dennis M , Rosenzweig, Anthony , Honigberg, Michael C , Castro, Claire , Karumanchi, S. Ananth , Ellinor, Patrick T. , Investigators, for the IPAC, Hilfiker‐Kleiner, Denise , Schelbert, Erik B. , Butler, Amy, Elkayam, Uri , Caro, Jorge , Rajagopalan, Navin , Booth, David, Cooper, Leslie T. , Briller, Joan Ellen , Felker, G. Michael , Kociol, Robb D. , Adams, Patricia, Wells, Gretchen , Michel, Caroline, Boehmer, John , Holloway, Joan, Powell, Maria, Drazner, Mark H. , Zucker, Mark Jay , Baran, David A. , Patel, Bharati, Gottlieb, Stephen S. , Farr, Maryjane , Bozkurt, Biykem , Maas, Elizabeth, Kleet, Audrey

Mayo Clinic

Science Translational Medicine | April 17, 2024 | Volume: 16 | Issue: 743 | Pages: No page available

10.1126/scitranslmed.adi0077 | PMID 38630848 Get It

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.
Machine learning in cardiac stress test interpretation: a systematic review
Barzilai, Dor Hadida , Cohen-Shelly, Michal , Sorin, Vera , Zimlichman, Eyal , Massalha, Eias , Allison, Thomas G. , Klang, Eyal , Hadida Barzilai, Dor

Mayo Clinic

European Heart Journal - Digital Health | April 17, 2024 | Volume: 5 | Issue: 4 | Pages: 401-408

10.1093/ehjdh/ztae027 | PMID 39081945 Get It

Abstract Coronary artery disease (CAD) is a leading health challenge worldwide. Exercise stress testing is a foundational non-invasive diagnostic tool. Nonetheless, its variable accuracy prompts the exploration of more reliable methods. Recent advancements in machine learning (ML), including deep learning and natural language processing, have shown potential in refining the interpretation of stress testing data. Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review of ML applications in stress electrocardiogram (ECG) and stress echocardiography for CAD prognosis. Medical Literature Analysis and Retrieval System Online, Web of Science, and the Cochrane Library were used as databases. We analysed the ML models, outcomes, and performance metrics. Overall, seven relevant studies were identified. Machine-learning applications in stress ECGs resulted in sensitivity and specificity improvements. Some models achieved rates of above 96% in both metrics and reduced false positives by up to 21%. In stress echocardiography, ML models demonstrated an increase in diagnostic precision. Some models achieved specificity and sensitivity rates of up to 92.7 and 84.4%, respectively. Natural language processing applications enabled the categorization of stress echocardiography reports, with accuracy rates nearing 98%. Limitations include a small, retrospective study pool and the exclusion of nuclear stress testing, due to its well-documented status. This review indicates the potential of artificial intelligence applications in refining CAD stress testing assessment. Further development for real-world use is warranted.